Literature DB >> 15817583

Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma.

Eldad J Dann1, Ron Epelbaum, Irit Avivi, Menachem Ben Shahar, Nissim Haim, Jacob M Rowe, Zeev Blumenfeld.   

Abstract

BACKGROUND: Intensive chemotherapy is widely used to improve the outcome of aggressive non-Hodgkin lymphoma (NHL). Since these regimens may cause premature ovarian failure (POF), the ovarian function was studied in 13 consecutive women aged < or =40 years, treated with four cycles of intensified CHOP (cyclophosphamide 2000-3000 mg/m2 per cycle doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 (maximum 2 mg) and prednisone 100 mg/day were given every 3 weeks).
METHODS: Patients aged <60 years with aggressive NHL were eligible for participating in a non-randomized phase II study if they had stage I, II, B, bulky, or stages III, IV disease with the age-adjusted international prognostic index of low-intermediate to high-risk score. Seven patients were concomitantly treated with D-TRP6-GnRH analogue (Decapeptyl; Ferring, Germany) for minimizing gonadal toxicity.
RESULTS: With a median follow-up of 70 months only one patient had POF, while 12 patients retained fertility and eight conceived spontaneously delivering 12 healthy babies.
CONCLUSION: It appears that high-dose cyclophosphamide does not affect the ovarian function or fertility in patients exposed to this medication during four consecutive cycles of intensified CHOP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15817583     DOI: 10.1093/humrep/dei018

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

Review 1.  Breast cancer and fertility preservation.

Authors:  S Samuel Kim; Jennifer Klemp; Carol Fabian
Journal:  Fertil Steril       Date:  2011-01-26       Impact factor: 7.329

Review 2.  Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications.

Authors:  Monika L Metzger; Lillian R Meacham; Briana Patterson; Jacqueline S Casillas; Louis S Constine; Nobuko Hijiya; Lisa B Kenney; Marcia Leonard; Barbara A Lockart; Wendy Likes; Daniel M Green
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

Review 3.  Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis.

Authors:  Megan E B Clowse; Millie A Behera; Carey K Anders; Susannah Copland; Cynthia J Coffman; Phyllis C Leppert; Lori A Bastian
Journal:  J Womens Health (Larchmt)       Date:  2009-03       Impact factor: 2.681

4.  Fertility in female survivors of Hodgkin's lymphoma.

Authors:  Irene Biasoli; Simona Falorio; Stefano Luminari; Nelson Spector; Massimo Federico
Journal:  Rev Bras Hematol Hemoter       Date:  2012

5.  Chemotherapy-Induced Amenorrhea - An Update.

Authors:  C Liedtke; L Kiesel
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-09       Impact factor: 2.915

6.  Hyaluronic acid prevents immunosuppressive drug-induced ovarian damage via up-regulating PGRMC1 expression.

Authors:  Guangfeng Zhao; Guijun Yan; Jie Cheng; Xue Zhou; Ting Fang; Haixiang Sun; Yayi Hou; Yali Hu
Journal:  Sci Rep       Date:  2015-01-06       Impact factor: 4.379

7.  Fertility Preservation in Female Patients with Breast Cancer - a Current Overview.

Authors:  Veronika Guenther; Ibrahim Alkatout; Wiebe Junkers; Dirk Bauerschlag; Nicolai Maass; Soeren von Otte
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-10-26       Impact factor: 2.915

Review 8.  Successful pregnancy via in vitro fertilization in a primary infertile woman with primary lymphoma of the fallopian tube after surgery: A case report and literature review.

Authors:  Jie Zhang; Zhen Hou; Jie Huang; Wei Xu; Cong Wang; Xiang Ma; Nan Lu; Jiayin Liu; Yundong Mao; Yi Qian
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.